Search 

Incuron is a private clinical-stage company that develops a novel class of synthetic small molecules, Curaxins, with a unique multi-targeted mechanism of antitumor activity. These chromatin damaging agents interfere with histone/DNA binding causing decondensation of chromatin in tumor cells, functional inactivation of histone chaperone FACT, and simultaneous effect on a set of universal previously undruggable targets, leading to inhibition of pro-cancer transcriptional factors, MYC, NF-kB, HIF1a, and HSF-1, and activation of the tumor suppressor p53, as well as induction of type I interferon response.
Key advantages of curaxins based on current preclinical and early clinical data include:
- novel mechanism of action that would bring the additional treatment option for advanced and relapsed tumors, as well as potential to overcome resistance to previous treatments;
- favorable pharmacology and manageable safety profiles;
- low potential for serious drug-drug interactions providing opportunities for combinatorial therapeutic regimens;
- broad activity in different tumor types that may open wider market opportunities;
- focused phase 2 clinical study program can establish faster clinical proof of concept and build toward accelerated regulatory approval.
Incuron owns a worldwide patent portfolio, including the composition of matter and therapeutic uses of the compounds.

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.

InorbitTX is a virtual drug discovery and development company focussed on the treatment of fatty liver diseases NAFLD / NASH. Its lead project, the FXR agonist IOT022 is currently in late pre-clinical testing. IOT022 differentiates very well from competitor compounds, as it mitigates the risk for pruritus and for drug induced liver injury, seen with competitors. It gives IOT022 an excellent best-in-class opportunity. InorbitTX second project is a KHK inhibitor, IOT038, also for the treatment of NAFLD / NASH.IOT038 shows excellent astute efficacy in animals We look for funding to complete for IND and for Phase I. We also look for partnering for the Chinese / Asian market.

Jemincare is a leading pharmaceutical group in China with $5.2B revenue in 2019. JeminCare is dedicated to providing novel healthcare solutions with Rx and OTC drugs with strategic fields in renal disease, oncology, cardiovascular, anti-infection, respiratory, and analgesic. We have a well-established marketing and sales network in China with a team of more than 5000 sales reps.

Located in Shanghai, Jemincare R&D center has 400+ experienced scientists and more than 30 novel prescription drugs in the pipeline.